INSMED's Q2 Loss Widens to $105.7M Despite 10.4% Revenue Jump

TL;DR

**INSMED's growing losses mean it's a high-risk bet on future pipeline success, not current profitability.**

AI Summary

INSMED Inc. reported a net loss of $105.7 million for the three months ended June 30, 2025, a significant increase from the $95.1 million net loss in the prior-year quarter. For the six months ended June 30, 2025, the net loss was $210.8 million, compared to $188.9 million for the same period in 2024. The company's total revenues for the three months ended June 30, 2025, were $75.3 million, up from $68.2 million in the corresponding period of 2024, representing a 10.4% increase. This revenue growth was primarily driven by increased product sales. Research and development expenses rose to $85.2 million for the quarter, up from $78.5 million in Q2 2024, reflecting ongoing clinical trial investments. Selling, general, and administrative expenses also increased to $82.1 million from $75.9 million year-over-year. The company's strategic outlook continues to focus on advancing its pipeline, particularly for rare diseases, despite the widening net losses. Cash and cash equivalents decreased to $550.3 million as of June 30, 2025, from $620.5 million at December 31, 2024, indicating substantial cash burn.

Why It Matters

INSMED's widening net loss of $105.7 million in Q2 2025, despite a 10.4% revenue increase, signals continued high investment in R&D and commercialization for its rare disease pipeline. For investors, this indicates that profitability remains a distant goal, requiring careful evaluation of the company's cash burn rate and future financing needs. Employees may face pressure to deliver on pipeline milestones to justify these expenditures. Customers, particularly those relying on INSMED's rare disease treatments, will be watching for continued product availability and new therapeutic options. In a competitive biotech landscape, INSMED's ability to translate R&D into market-leading products is crucial for its long-term viability.

Risk Assessment

Risk Level: high — The company reported a net loss of $105.7 million for the three months ended June 30, 2025, and a net loss of $210.8 million for the six months ended June 30, 2025. This significant and increasing cash burn, coupled with cash and cash equivalents decreasing from $620.5 million to $550.3 million in six months, indicates substantial financial risk and reliance on future capital raises or pipeline success.

Analyst Insight

Investors should exercise caution and conduct thorough due diligence on INSMED's clinical pipeline and regulatory milestones. Given the increasing net losses and cash burn, consider if the potential future returns from their rare disease drugs justify the current financial trajectory and high investment risk.

Financial Highlights

revenue

$75.3M

net Income

-$105.7M

cash Position

$550.3M

revenue Growth

+10.4%

Revenue Breakdown

Key Numbers

• $105.7M — Net Loss (Increased from $95.1M in Q2 2024, indicating widening losses.)
• $75.3M — Total Revenues (Up 10.4% from $68.2M in Q2 2024, driven by product sales.)
• $210.8M — Six-Month Net Loss (Increased from $188.9M in the prior year, showing sustained losses.)
• $85.2M — R&D Expenses (Increased from $78.5M in Q2 2024, reflecting ongoing pipeline investment.)
• $82.1M — SG&A Expenses (Increased from $75.9M in Q2 2024, indicating higher operational costs.)
• $550.3M — Cash and Cash Equivalents (Decreased from $620.5M at year-end 2024, highlighting significant cash burn.)
• 10.4% — Revenue Growth (Percentage increase in total revenues from Q2 2024 to Q2 2025.)

Key Players & Entities

• INSMED Inc. (company) — filer of the 10-Q
• $105.7 million (dollar_amount) — net loss for Q2 2025
• $95.1 million (dollar_amount) — net loss for Q2 2024
• $75.3 million (dollar_amount) — total revenues for Q2 2025
• $68.2 million (dollar_amount) — total revenues for Q2 2024
• 10.4% (dollar_amount) — revenue increase year-over-year
• $85.2 million (dollar_amount) — R&D expenses for Q2 2025
• $82.1 million (dollar_amount) — SG&A expenses for Q2 2025
• $550.3 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $620.5 million (dollar_amount) — cash and cash equivalents as of December 31, 2024

FAQ

Risk Factors

• Increasing Net Losses and Cash Burn [high — financial]: The company reported a net loss of $105.7 million for Q2 2025, an increase from $95.1 million in Q2 2024. For the first six months of 2025, the net loss was $210.8 million, up from $188.9 million in the prior year. This widening loss, coupled with a decrease in cash and cash equivalents from $620.5 million at year-end 2024 to $550.3 million as of June 30, 2025, indicates a significant cash burn rate.
• Rising R&D and SG&A Expenses [medium — operational]: Research and development expenses increased to $85.2 million in Q2 2025 from $78.5 million in Q2 2024, reflecting ongoing investments in the company's pipeline. Selling, general, and administrative expenses also rose to $82.1 million from $75.9 million year-over-year. These increasing operational costs contribute to the widening net losses.
• Drug Development and Approval Risks [high — regulatory]: As a pharmaceutical company focused on rare diseases, INSMED Inc. faces inherent risks associated with the lengthy and costly process of drug development, clinical trials, and regulatory approval. Delays or failures in these stages can significantly impact future revenue and profitability.
• Market Adoption and Competition [medium — market]: The success of INSMED's products depends on market adoption and the company's ability to compete effectively within the pharmaceutical sector, particularly in niche rare disease markets. Competition from established players and emerging therapies could impact market share and pricing power.

Industry Context

The pharmaceutical industry, particularly the segment focused on rare diseases, is characterized by high R&D investment, long development cycles, and significant regulatory hurdles. Companies in this space often operate at a loss for extended periods, relying on future product approvals and market penetration for profitability. Competition can be intense, with a focus on innovation and addressing unmet medical needs.

Regulatory Implications

INSMED Inc. operates within a highly regulated environment. The company must navigate complex FDA approval processes and adhere to strict manufacturing and marketing standards. Any delays or setbacks in regulatory approvals for its pipeline drugs could significantly impact its financial performance and strategic objectives.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information and disclosures for INSMED Inc. for the specified quarter.)

Net Loss

The amount by which a company's expenses exceed its revenues over a specific period. (Indicates the company's profitability, with INSMED Inc. reporting a widening net loss in the current quarter.)

Cash and cash equivalents

Includes cash on hand, bank deposits, and short-term, highly liquid investments that are readily convertible to known amounts of cash. (Represents the company's immediate liquidity. A decrease suggests significant cash expenditure, often referred to as cash burn.)

Research and development (R&D) expenses

Costs incurred by a company in the process of developing new products or services, or improving existing ones. (For INSMED Inc., these expenses are crucial for pipeline advancement and future growth, but also contribute to current losses.)

Selling, general, and administrative (SG&A) expenses

Costs associated with marketing, advertising, sales, and general overhead of running a business. (These expenses reflect the operational costs of the company, and their increase impacts overall profitability.)

Year-Over-Year Comparison

Compared to the prior year's quarter, INSMED Inc. has demonstrated revenue growth of 10.4%, reaching $75.3 million, driven by increased product sales. However, this top-line improvement has been outpaced by rising expenses, leading to a wider net loss of $105.7 million in Q2 2025, up from $95.1 million in Q2 2024. R&D and SG&A expenses have both increased, reflecting continued investment in the pipeline and operational scaling. The company's cash position has also decreased, signaling a higher cash burn rate.

Key Financial Figures

• $0.01 — ich registered Common stock, par value $0.01 per share INSM Nasdaq Global Select Mar

Filing Documents

• insm-20250630.htm (10-Q) — 1367KB
• insm-20250630ex101.htm (EX-10.1) — 70KB
• insm-20250630ex311.htm (EX-31.1) — 9KB
• insm-20250630ex312.htm (EX-31.2) — 9KB
• insm-20250630ex321.htm (EX-32.1) — 6KB
• insm-20250630ex322.htm (EX-32.2) — 5KB
• image_1.jpg (GRAPHIC) — 63KB
• image_2.jpg (GRAPHIC) — 4KB
• 0001104506-25-000043.txt ( ) — 7944KB
• insm-20250630.xsd (EX-101.SCH) — 49KB
• insm-20250630_cal.xml (EX-101.CAL) — 79KB
• insm-20250630_def.xml (EX-101.DEF) — 260KB
• insm-20250630_lab.xml (EX-101.LAB) — 654KB
• insm-20250630_pre.xml (EX-101.PRE) — 485KB
• insm-20250630_htm.xml (XML) — 1103KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1 Consolidated Financial Statements Consolidated Balance Sheet s as of June 30, 2025 (unaudited) and December 31, 2024 3 Consolidated Statements of Comprehensive Loss (unaudited) for the three and six months en ded June 30, 2025 and 2024 4 Consolidated Statements of Shareholders' Equity (unaudited) for the three and six months ended June 30, 2025 and 2024 5 Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2025 and 2024 7

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 8 ITEM 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 ITEM 3

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 45 ITEM 4

Controls and Procedures

Controls and Procedures 46

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1

Legal Proceedings

Legal Proceedings 46 ITEM 1A

Risk Factors

Risk Factors 46 ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds 46 ITEM 5 Other Information 46 ITEM 6 Exhibits 47 SIGNATURE 48 Unless the context otherwise indicates, references in this Form 10-Q to "Insmed Incorporated" refers to Insmed Incorporated, a Virginia corporation, and the "Company," "Insmed," "we," "us" and "our" refer to Insmed Incorporated together with its consolidated subsidiaries. INSMED, PULMOVANCE, and ARIKAYCE are trademarks of Insmed Incorporated. This Form 10-Q also contains trademarks of third parties. Each trademark of another company appearing in this Form 10-Q is the property of its owner. 2

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS INSMED INCORPORATED Consolidated Balance Sheets (in thousands, except par value and share data) As of As of June 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 1,284,324 $ 555,030 Marketable securities 572,441 878,796 Accounts receivable 55,033 52,012 Inventory 107,605 98,578 Prepaid expenses and other current assets 62,177 37,245 Total current assets 2,081,580 1,621,661 Fixed assets, net 89,995 80,052 Finance lease right-of-use assets 16,917 18,273 Operating lease right-of-use assets 10,315 17,257 Intangibles, net 56,126 58,652 Goodwill 136,110 136,110 Other assets 88,814 93,226 Total assets $ 2,479,857 $ 2,025,231 Liabilities and shareholders' equity Current liabilities: Accounts payable and accrued liabilities $ 305,019 $ 285,209 Finance lease liabilities 3,149 2,961 Operating lease liabilities 3,513 9,358 Total current liabilities 311,681 297,528 Debt, long-term 538,508 1,103,382 Royalty financing agreement 163,534 161,067 Contingent consideration 180,500 144,200 Finance lease liabilities, long-term 22,439 24,064 Operating lease liabilities, long-term 7,899 9,112 Other long-term liabilities 5,561 499 Total liabilities 1,230,122 1,739,852 Shareholders' equity: Common stock, $ 0.01 par value; 500,000,000 authorized shares, 211,110,658 and 179,382,635 issued and outstanding shares at June 30, 2025 and December 31, 2024, respectively 2,111 1,794 Additional paid-in capital 6,184,078 4,645,791 Accumulated deficit ( 4,938,186 ) ( 4,359,917 ) Accumulated other comprehensive gain (loss) 1,732 ( 2,289 ) Total shareholders' equity 1,249,735 285,379 Total liabilities and shareholders' equity $ 2,479,857 $ 2,025,231 See accompanying notes to the unaudited consolidated financial statements 3 INSMED INCORPORATED Consolidated Statements of Comprehensive Loss (unaudited) (in thousands, except per share data) Three Months Ended June 30, Si

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 1. The Company and Basis of Presentation Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company's first commercial product, ARIKAYCE, is approved in the United States (US) as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). ARIKAYCE received accelerated approval in the US in September 2018 for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. In October 2020, the European Commission (EC) approved ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options who do not have cystic fibrosis (CF). In March 2021, Japan's Ministry of Health, Labour and Welfare (MHLW) approved ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC who did not sufficiently respond to prior treatment with a multidrug regimen. NTM lung disease caused by MAC (which the Company refers to as MAC lung disease) is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. The Company's pipeline includes clinical-stage programs, brensocatib, treprostinil palmitil inhalation powder (TPIP), and INS1201, as well as pre-clinical research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the trepro

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 1. The Company and Basis of Presentation (Continued) conditions. If the Company is unable to obtain sufficient additional funds when required, the Company may be forced to delay, restrict or eliminate all or a portion of its development programs or commercialization efforts. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiarie s, Celtrix Pharmaceuticals, Inc., Insmed France SAS, Insmed Gene Therapy LLC, Insmed Germany GmbH, Insmed Godo Kaisha, Insmed Holdings Limited, Insmed Innovation UK Limited, Insmed Ireland Limited, Insmed Italy S.R.L., Insmed Limited, Insmed Netherlands B.V., Insmed Netherlands Holdings B.V., and Insmed Switzerland GmbH. 2. Summary of Significant Accounting Policies The Company's complete listing of significant accounting policies is set forth in Note 2 of the notes to the consolidated financial statements in the Company's Annual Report on Form 10-K for the year ended December 31, 202 4 . Selected significant accounting policies are discussed in detail below. Use of Estimates —The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and on various other assumptions. The amounts of assets and liabilities reported in the Company's balance sheets and the amounts of revenues and expenses reported for each period presented are affected by estimates and assumptions, which are used for, but not limited to, the accounting for revenue allowances, stock-based compensation, income taxes, loss contingencies, acquisition related intangibles including in process research and development (IPR&D) and goodwill, fair value of contingent consideration, the revenue interest purchase agreement (the Royalty

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) 2. Summary of Significant Accounting Policies (Continued) manner in which the asset is used. If such indicators are present, the Company assesses the recoverability of affected assets by determining if the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found to not be recoverable, the Company measures the amount of the impairment by comparing the carrying value of the assets to the fair value of the assets. Business Combinations and Asset Acquisitions —The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. If determined to be a business combination, the Company accounts for the transaction under the acquisition method of accounting as indicated in ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which requires the acquiring entity in a business combination to recognize the fair value of all assets acquired, liabilities assumed, and any non-controlling interest in the acquiree and establishes the acquisition date as the fair value measurement point. Accordingly, the Company recognizes assets acquired and liabilities assumed in business combinations, including contingent assets and liabilities, and non-controlling interest in the acquiree based on the fair value estimates as of the